Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Recurrence 1Peritoneal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma in Situ 1Abdominal Neoplasms 1

Interventions

Paclitaxel 115Carboplatin 114Cisplatin 46Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28Bevacizumab 28liposomal doxorubicin 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 13sargramostim 12olaparib 12Immunohistochemistry 11Chemotherapy, Adjuvant 11Surgical Procedures, Operative 10Therapeutics 9Flow Cytometry 9Etoposide 9oregovomab 8niraparib 8mirvetuximab soravtansine 8Psychiatric Rehabilitation 8Nivolumab 8Amifostine 8rucaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Cell Count × Gynecologic × Clear all
NCT05617755 2025-07-30

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Arsenal Biosciences, Inc.

Phase 1 Active not recruiting
19 enrolled
Gynecologic

Abdominal Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡